Immune cells inside a brain tumor may help it resist treatment
Original title: Microenvironment-derived acetylated amino acids promote glioblastoma treatment resistance.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done in lab models and tissue samples, not in people.
The short version
Early lab work suggests nearby immune cells feed glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary cells and help them survive treatment.
What was studied. Researchers studied glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary, a fast-growing brain tumor. They used patient tissue samples and lab models to look at immune cells called macrophages that live in and around the tumor.
What they found. The macrophages gave off substances called acetylated amino acids. Tumor cells took these in and used them to repair damaged DNA faster. That made treatment work less well. When the team blocked a protein called KAT5, the tumor cells lost that protection.
What this means, and what it doesn't
What it could mean: If this holds up, blocking this feeding step might one day help brain tumor treatment work better. Right now it gives researchers a new target to test.
What it doesn't mean: This does not mean there is a new treatment. The work was done in tissue samples and lab models, not in a trial of people. No one knows yet if blocking this step would help patients live longer. It is not a cure, and it is not something a doctor can offer today.
Source: PubMed, September 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.